De-regulation of RET signaling by oncogenic mutation, gene rearrangement,
overexpression or transcriptional up-regulation is implicated in several human cancers of …

The receptor tyrosine kinase RET is expressed in cell lineages derived from the neural crest
and has a key role in regulating cell proliferation, migration, differentiation and survival …

It has been twenty-five years since the discovery of oncogenic germline RET mutations as
the cause of multiple endocrine neoplasia type 2 (MEN2). Intensive work over the last two …

Endocrine therapy is the main therapeutic option for patients with estrogen receptor (ERα)-
positive breast cancer. Resistance to this treatment is often associated with estrogen …

By screening a tissue microarray of invasive breast tumors, we have shown that the receptor
tyrosine kinase RET (REarranged during Transfection) and its coreceptor GFRα1 (GDNF …

To decipher the molecular basis for RET kinase activation and oncogenic deregulation, we
defined the temporal sequence of RET autophosphorylation by label-free quantitative mass …

Most breast cancers at diagnosis are estrogen receptor-positive (ER+) and depend on
estrogen for growth and survival. Blocking estrogen biosynthesis by aromatase inhibitors …

Germ line missense mutations in the RET (rearranged during transfection) oncogene are the
cause of multiple endocrine neoplasia, type 2 (MEN2), but at present surgery is the only …

Autophosphorylation controls the transition between discrete functional and conformational
states in protein kinases, yet the structural and molecular determinants underlying this …

RET kinase is aberrantly activated in thyroid cancers and in rare cases of lung and colon
cancer, and has been validated as a molecular target in these tumors. Vandetanib was …